Clinical and Translational Radiation Oncology

Papers
(The H4-Index of Clinical and Translational Radiation Oncology is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
COVID-19: Global radiation oncology’s targeted response for pandemic preparedness143
4D-MRI driven MR-guided online adaptive radiotherapy for abdominal stereotactic body radiation therapy on a high field MR-Linac: Implementation and initial clinical experience62
The tumor microenvironment and radiotherapy response; a central role for cancer-associated fibroblasts61
Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: Initial clinical experiences and assessment of delivered doses compared to a C-arm linac48
Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment47
A review of the role of MRI in diagnosis and treatment of early stage lung cancer35
The technical design and concept of a PET/CT linac for biology-guided radiotherapy35
Marker-less online MR-guided stereotactic body radiotherapy of liver metastases at a 1.5 T MR-Linac – Feasibility, workflow data and patient acceptance28
Evaluation of daily online contour adaptation by radiation therapists for prostate cancer treatment on an MRI-guided linear accelerator27
Evaluation of deep learning-based multiparametric MRI oropharyngeal primary tumor auto-segmentation and investigation of input channel effects: Results from a prospective imaging registry23
Whole Brain Irradiation or Stereotactic RadioSurgery for five or more brain metastases (WHOBI-STER): A prospective comparative study of neurocognitive outcomes, level of autonomy in daily activities a21
Feasibility of magnetic resonance guided radiotherapy for the treatment of bladder cancer21
Radiomic biomarkers of tumor immune biology and immunotherapy response20
CDK 4/6 inhibitors combined with radiotherapy: A review of literature19
NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience18
Dose-dependent volume loss in subcortical deep grey matter structures after cranial radiotherapy17
Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma17
0.037491083145142